Autopsy report · NCT01460602

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

“Investigator has relocated to MD Anderson”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Louisiana State University Health Sciences Center Shreveport

Sponsor type

University, hospital or other

Conditions

Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma

Interventions

MTD of Velcade, Nipent and Rituxan established in Part 1

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Dupilumab Phase 4 Study
  “Investigator moved from institution.” (68% match in meaning)
• Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis
  “Original investigator left this institution, replacement investigator retired.” (63% match in meaning)
• Whole Body Hyperthermia Registry Study
  “Investigator transferred to the University of Wisconsin - Madison” (62% match in meaning)
• Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations
  “Investigator departed from institution” (62% match in meaning)
• Trial of Art Therapy During Cognitive Processing Therapy for PTSD
  “Investigator has retired.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.